Kanpur Samachar

DelveInsight’s “Advanced Renal Cell Carcinoma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Antibody Drug Conjugates, historical and forecasted epidemiology as well as the Antibody Drug Conjugates market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Advanced Renal Cell Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Advanced Renal Cell Carcinoma Market Forecast

Some of the key facts of the Advanced Renal Cell Carcinoma Market Report:

• The Advanced Renal Cell Carcinoma market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In February 2025, Updated results from a phase 1 study (NCT05122546) presented at the 2025 Genitourinary Cancers Symposium revealed that the combination of CBM588 with cabozantinib (Cabometyx) and nivolumab (Opdivo) enhanced progression-free survival (PFS) and objective response rate (ORR) in patients with metastatic renal cell carcinoma (mRCC), though it did not result in a significant rise in Bifidobacterium spp. levels.

• In December 2024, Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotech company focused on developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases, has announced that the first patient has been dosed in its Phase 1 clinical trial investigating ADI-270 in individuals with metastatic or advanced clear cell renal cell carcinoma (ccRCC)

• In October 2024, Arcus Biosciences revealed a clinical trial collaboration with AstraZeneca to evaluate the combined use of casdatifan (AB521) and volrustomig in treating patients with clear cell renal cell carcinoma (ccRCC). Casdatifan is Arcus’ experimental HIF-2α inhibitor, while volrustomig is AstraZeneca’s investigational bispecific antibody targeting PD-1 and CTLA-4. Under the terms of the agreement, AstraZeneca will be responsible for sponsoring and conducting the trial.

• The Canadian Medical Association Journal (CMAJ) of 2024 states that the occurrence of RCC rises as individuals get older, typically diagnosed around the age of 75 globally. Additionally, males are twice as likely as females to develop this condition.

• As per the Canadian Medical Association Journal (CMAJ) in 2024, the general survival expectancy for metastatic RCC is roughly 4 years. Nevertheless, this duration may fluctuate based on variables like the patient’s age, performance level, and any accompanying health conditions.

• Key Advanced Renal Cell Carcinoma Companies: Dana-Farber Cancer Institute, Huabo Biopharm Co., Ltd., Beijing Scitech-Mq Pharmaceuticals, Oxford BioMedica, Hutchison Medipharma Limited, Takeda, Amgen, Novartis, AVEO Pharmaceuticals, Inc., Merck Sharp & Dohme LLC, Pfizer, Calithera Biosciences, Inc, AbbVie, Bristol-Myers Squibb, Abbott, SCRI Development Innovations, LLC, Astellas Pharma Inc, and others

• Key Advanced Renal Cell Carcinoma Therapies: Bevacizumab, HB0025, ST-1898 tablets, Trovax, fruquintinib+sintilimab, Cabozantinib, AMG 102, Pazopanib, tivozanib (AV-951), Belzutifan, Temsirolimus (CCI-779), CB-839, ABT-869, Nivolumab, ABT-510/Thrombospondin-1 mimetic, bevacizumab, CP-461, and others

• The Advanced Renal Cell Carcinoma epidemiology based on gender analyzed that Males are slightly more affected in the case of Advanced Renal Cell Carcinoma

• The Advanced Renal Cell Carcinoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Advanced Renal Cell Carcinoma pipeline products will significantly revolutionize the Advanced Renal Cell Carcinoma market dynamics.

Advanced Renal Cell Carcinoma Overview

Advanced Renal Cell Carcinoma (RCC), also known as advanced kidney cancer, refers to cancer that has spread beyond the kidney and nearby lymph nodes to other parts of the body. Renal cell carcinoma originates in the cells of the kidney’s tubules, which are tiny tubes that filter blood and remove waste products to form urine.

Get a Free sample for the Advanced Renal Cell Carcinoma Market Report:

https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-market

Advanced Renal Cell Carcinoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Advanced Renal Cell Carcinoma Epidemiology Segmentation:

The Advanced Renal Cell Carcinoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Advanced Renal Cell Carcinoma

• Prevalent Cases of Advanced Renal Cell Carcinoma by severity

• Gender-specific Prevalence of Advanced Renal Cell Carcinoma

• Diagnosed Cases of Episodic and Chronic Advanced Renal Cell Carcinoma

Download the report to understand which factors are driving Advanced Renal Cell Carcinoma epidemiology trends @ Advanced Renal Cell Carcinoma Epidemiology Forecast

Advanced Renal Cell Carcinoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Advanced Renal Cell Carcinoma market or expected to get launched during the study period. The analysis covers Advanced Renal Cell Carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Advanced Renal Cell Carcinoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Advanced Renal Cell Carcinoma Therapies and Key Companies

• Bevacizumab: Dana-Farber Cancer Institute

• HB0025: Huabo Biopharm Co., Ltd.

• ST-1898 tablets: Beijing Scitech-Mq Pharmaceuticals

• Trovax: Oxford BioMedica

• fruquintinib+sintilimab: Hutchison Medipharma Limited

• Cabozantinib: Takeda

• AMG 102: Amgen

• Pazopanib: Novartis

• tivozanib (AV-951): AVEO Pharmaceuticals, Inc.

• Belzutifan: Merck Sharp & Dohme LLC

• Temsirolimus (CCI-779): Pfizer

• CB-839: Calithera Biosciences, Inc

• ABT-869: AbbVie

• Nivolumab: Bristol-Myers Squibb

• ABT-510/Thrombospondin-1 mimetic: Abbott

• bevacizumab: SCRI Development Innovations, LLC

• CP-461: Astellas Pharma Inc

Discover more about therapies set to grab major Advanced Renal Cell Carcinoma market share @ Advanced Renal Cell Carcinoma Treatment Landscape

Advanced Renal Cell Carcinoma Market Strengths

• The incidence of RCC has increased in recent years leading to more focus by pharmaceutical firms.

• Antiangiogenics in association with targeted immunotherapy is overcoming resistance emphasizing the role of the tumor microenvironment (TME) and this strategy is currently an option in first line treatment.

Advanced Renal Cell Carcinoma Market Opportunities

• There are ongoing trials addressing unanswered questions, such as (CAR) T-cell therapy.

Scope of the Advanced Renal Cell Carcinoma Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Advanced Renal Cell Carcinoma Companies: Dana-Farber Cancer Institute, Huabo Biopharm Co., Ltd., Beijing Scitech-Mq Pharmaceuticals, Oxford BioMedica, Hutchison Medipharma Limited, Takeda, Amgen, Novartis, AVEO Pharmaceuticals, Inc., Merck Sharp & Dohme LLC, Pfizer, Calithera Biosciences, Inc, AbbVie, Bristol-Myers Squibb, Abbott, SCRI Development Innovations, LLC, Astellas Pharma Inc, and others

• Key Advanced Renal Cell Carcinoma Therapies: Bevacizumab, HB0025, ST-1898 tablets, Trovax, fruquintinib+sintilimab, Cabozantinib, AMG 102, Pazopanib, tivozanib (AV-951), Belzutifan, Temsirolimus (CCI-779), CB-839, ABT-869, Nivolumab, ABT-510/Thrombospondin-1 mimetic, bevacizumab, CP-461, and others

• Advanced Renal Cell Carcinoma Therapeutic Assessment: Advanced Renal Cell Carcinoma current marketed and Advanced Renal Cell Carcinoma emerging therapies

• Advanced Renal Cell Carcinoma Market Dynamics: Advanced Renal Cell Carcinoma market drivers and Advanced Renal Cell Carcinoma market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

Table of Contents

1. Advanced Renal Cell Carcinoma Market Report Introduction

2. Executive Summary for Advanced Renal Cell Carcinoma

3. SWOT analysis of Advanced Renal Cell Carcinoma

4. Advanced Renal Cell Carcinoma Patient Share (%) Overview at a Glance

5. Advanced Renal Cell Carcinoma Market Overview at a Glance

6. Advanced Renal Cell Carcinoma Disease Background and Overview

7. Advanced Renal Cell Carcinoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Advanced Renal Cell Carcinoma

9. Advanced Renal Cell Carcinoma Current Treatment and Medical Practices

10. Advanced Renal Cell Carcinoma Unmet Needs

11. Advanced Renal Cell Carcinoma Emerging Therapies

12. Advanced Renal Cell Carcinoma Market Outlook

13. Country-Wise Advanced Renal Cell Carcinoma Market Analysis (2020–2034)

14. Advanced Renal Cell Carcinoma Market Access and Reimbursement of Therapies

15. Advanced Renal Cell Carcinoma Market Drivers

16. Advanced Renal Cell Carcinoma Market Barriers

17. Advanced Renal Cell Carcinoma Appendix

18. Advanced Renal Cell Carcinoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/